CA3013336A1 - Buffer formulations for enhanced antibody stability - Google Patents

Buffer formulations for enhanced antibody stability Download PDF

Info

Publication number
CA3013336A1
CA3013336A1 CA3013336A CA3013336A CA3013336A1 CA 3013336 A1 CA3013336 A1 CA 3013336A1 CA 3013336 A CA3013336 A CA 3013336A CA 3013336 A CA3013336 A CA 3013336A CA 3013336 A1 CA3013336 A1 CA 3013336A1
Authority
CA
Canada
Prior art keywords
antibody formulation
formulation
buffered
antibody
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3013336A
Other languages
English (en)
French (fr)
Inventor
Hiten GUTKA
Maria TADDEI
Jessica CHEUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Outlook Therapeutics Inc
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of CA3013336A1 publication Critical patent/CA3013336A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3013336A 2016-02-03 2017-02-01 Buffer formulations for enhanced antibody stability Pending CA3013336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290654P 2016-02-03 2016-02-03
US62/290,654 2016-02-03
PCT/US2017/016040 WO2017136433A1 (en) 2016-02-03 2017-02-01 Buffer formulations for enhanced antibody stability

Publications (1)

Publication Number Publication Date
CA3013336A1 true CA3013336A1 (en) 2017-08-10

Family

ID=58046768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013336A Pending CA3013336A1 (en) 2016-02-03 2017-02-01 Buffer formulations for enhanced antibody stability

Country Status (8)

Country Link
US (1) US11285210B2 (https=)
EP (1) EP3411401A1 (https=)
JP (1) JP7084308B2 (https=)
CN (1) CN109563161A (https=)
AU (1) AU2017213775A1 (https=)
CA (1) CA3013336A1 (https=)
MX (1) MX2018009341A (https=)
WO (1) WO2017136433A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
KR20210102954A (ko) * 2019-01-11 2021-08-20 삼성바이오에피스 주식회사 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도
CA3155065A1 (en) * 2019-09-19 2021-03-25 Innovent Biologics (Suzhou) Co., Ltd. Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof
TW202304507A (zh) * 2021-04-02 2023-02-01 美商再生元醫藥公司 含有抗muc16x抗cd3雙特異性抗體之穩定調配物
GB202115121D0 (en) * 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) * 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013876A1 (en) 1991-02-01 1992-08-20 Coulter Corporation METHOD OF PRODUCING F(ab')2 FRAGMENTS OF IMMUNOGLOBULINS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 TNFα를 억제하는 안정적이고 가용성인 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
EP2077325A4 (en) 2006-09-11 2012-04-11 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
ES2442258T3 (es) 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
NZ580378A (en) 2007-03-30 2012-11-30 Abbott Lab Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
WO2008136398A1 (ja) 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
WO2008150491A2 (en) 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
ATE460666T1 (de) 2008-01-15 2010-03-15 Univ Utrecht Holding Bv Verfahren zur bestimmung der aminosäurensequenz von peptiden
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
JP2011517672A (ja) 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MX2011004198A (es) 2008-10-20 2011-05-24 Abbott Lab Anticerpos que unen a il-12 y metodos para purificar los mismos.
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
CN102348979A (zh) 2009-03-09 2012-02-08 乔治亚大学研究基金公司 胃癌诊断用蛋白标记的鉴定
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
SG10201503899SA (en) 2010-05-18 2015-06-29 Abbvie Inc Apparatus And Process Of Purification Of Proteins
KR101976853B1 (ko) 2010-05-25 2019-05-09 제넨테크, 인크. 폴리펩티드의 정제 방법
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
JP6010030B2 (ja) 2010-09-20 2016-10-19 アッヴィ・インコーポレイテッド 疑似移動床クロマトグラフィーを使用する抗体の精製
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP2627425A4 (en) 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
CN103282509A (zh) 2010-12-28 2013-09-04 中外制药株式会社 动物细胞的培养方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CA2850668A1 (en) 2011-10-04 2013-04-11 Expression Pathology, Inc. Srm/mrm assay for the ephrin type-a receptor 2 protein
PE20141545A1 (es) 2011-10-24 2014-11-26 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013114165A1 (en) 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
JP5874587B2 (ja) 2012-09-10 2016-03-02 株式会社島津製作所 アミノ酸配列解析方法及び装置
NO2760138T3 (https=) 2012-10-01 2018-08-04
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company タンパク質を製造するための哺乳動物細胞培養方法
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2938323A2 (en) 2012-12-28 2015-11-04 Abbott Cardiovascular Systems, Inc. Therapeutic compositions comprising antibodies
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151901A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
JP6465794B2 (ja) 2013-04-25 2019-02-06 株式会社カネカ Fab型抗体の分泌量を増大できるFd鎖遺伝子又はL鎖遺伝子
WO2014182658A1 (en) 2013-05-06 2014-11-13 Abbvie Inc. Compositions for cell culture and methods of using the same
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3114476A4 (en) 2013-10-03 2017-11-01 Bioanalytix, Inc. Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
CN105044222B (zh) 2014-12-19 2017-09-12 浙江辉肽生命健康科技有限公司 生物活性多肽的分析测试和鉴定方法
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
CN105779394B (zh) 2015-03-20 2020-03-24 广东东阳光药业有限公司 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
CA3010600A1 (en) 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN109153716A (zh) 2016-01-06 2019-01-04 安口生物公司 调节单克隆抗体组合物中的非岩藻糖基化物类
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
AU2017214586A1 (en) 2016-02-04 2018-08-16 Outlook Therapeutics, Inc. Methods for identifying and analyzing amino acid sequences of proteins

Also Published As

Publication number Publication date
WO2017136433A1 (en) 2017-08-10
CN109563161A (zh) 2019-04-02
MX2018009341A (es) 2019-05-15
JP2019504086A (ja) 2019-02-14
US11285210B2 (en) 2022-03-29
EP3411401A1 (en) 2018-12-12
US20190030163A1 (en) 2019-01-31
AU2017213775A1 (en) 2018-08-16
JP7084308B2 (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
US11285210B2 (en) Buffer formulations for enhanced antibody stability
US10772960B2 (en) Stable aqueous formulations of adalimumab
AU2014337263B2 (en) Buffer formulations for enhanced antibody stability
DK2946765T3 (en) Liquid pharmaceutical composition
CN107635581A (zh) 用于单克隆抗体的稳定液体制剂
AU2016382786A1 (en) Buffered formulations of bevacizumab
TWI787161B (zh) 含有抗人類tslp受體抗體之醫藥組成物
CN104010658A (zh) 使用葡甲胺稳定的依那西普制剂
AU2012244764A1 (en) Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
HUE035707T2 (en) Pharmaceutical composition containing a biological drug
JP2022547162A (ja) 抗IL-23p19抗体製剤
TWI771335B (zh) 穩定藥學調配物
HK1230934B (zh) 用於提高抗体稳定性的缓冲液制剂
HK1230934A1 (en) Buffer formulations for enhanced antibody stability
HK1204921B (en) Stable liquid formulation of etanercept
HK1204921A1 (en) Stable liquid formulation of etanercept
HK1200720B (en) Etanercept formulations stabilized with combinations of sugars and polyols

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220128